Colorectal neoplasm
MONDO:0005335A benign or malignant neoplasm that affects the colon or rectum. Representative examples of benign neoplasms include lipoma and leiomyoma. Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma. Colorectal adenomas always exhibit epithelial dysplasia and are considered premalignant neoplasms.
Also known as: colorectal neoplasm, colorectal tumor, colorectal tumour, colorectum neoplasm, colorectum neoplasm (disease), colorectum tumor, colorectum tumour, large bowel neoplasm
4174 clinical trials for this condition and its sub-types, 1492 tagged with Colorectal neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Colorectal neoplasm
-
Colorectal cancer 1,767 trials · 2,697 incl. sub-types
5 sub-types
- Colorectal carcinoma 305 trials · 1,166 incl. sub-types Sub-types →
- Rectal cancer 433 trials · 633 incl. sub-types Sub-types →
- Malignant colon neoplasm 62 trials · 437 incl. sub-types Sub-types →
- Familial colorectal cancer 3 trials · 91 incl. sub-types Sub-types →
- Colorectal lymphoma 0 trials Sub-types →
-
Rectal neoplasm 433 trials · 690 incl. sub-types
4 sub-types
- Rectal cancer 433 trials · 633 incl. sub-types Sub-types →
- Epithelial neoplasm of rectum 0 trials · 398 incl. sub-types Sub-types →
- Anus neoplasm 87 trials · 140 incl. sub-types Sub-types →
- Benign neoplasm of rectum 2 trials Sub-types →
-
Colonic neoplasm 459 trials · 633 incl. sub-types
8 sub-types
- Malignant colon neoplasm 62 trials · 437 incl. sub-types Sub-types →
- Epithelial tumor of colon 0 trials · 407 incl. sub-types Sub-types →
- Cecal neoplasm 0 trials · 59 incl. sub-types Sub-types →
- Sigmoid neoplasm 7 trials · 17 incl. sub-types Sub-types →
- Colon neuroendocrine neoplasm 0 trials · 5 incl. sub-types Sub-types →
- Benign colon neoplasm 2 trials Sub-types →
- Colon inflammatory polyp 0 trials
- Colon juvenile polyp 0 trials
-
Colorectal adenoma 96 trials · 120 incl. sub-types
4 sub-types
- Colon adenoma 17 trials · 32 incl. sub-types Sub-types →
- Colorectal sessile serrated adenoma/polyp 11 trials · 13 incl. sub-types Sub-types →
- Rectum adenoma 5 trials · 6 incl. sub-types Sub-types →
- Colorectal tubulovillous adenoma 1 trial Sub-types →
-
Colorectal neuroendocrine tumor G1 1 trial · 4 incl. sub-types
2 sub-types
- Colon neuroendocrine tumor G1 1 trial · 3 incl. sub-types Sub-types →
- Rectal neuroendocrine tumor G1 1 trial
-
Colorectal hamartoma 0 trials
1 sub-type
- Colorectal juvenile polyp 0 trials Sub-types →
-
Colorectal leiomyoma 0 trials
2 sub-types
- Colon leiomyoma 0 trials Sub-types →
- Rectum leiomyoma 0 trials Sub-types →
Most studied deeper sub-types
Showing the 400 most recently updated of 819 trials in this tab.
-
Custom-Built immune cells take aim at a notorious cancer mutation
Cure OngoingResearchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Can a shorter radiation course spare the rectum in rectal cancer?
Cure OngoingThis phase 3 trial tests two different ways of using radiation before chemotherapy in people with stage III rectal cancer. One group gets a short course of radiation, the other gets standard chemoradiation, both followed by chemotherapy. The goal is to see if either approach can …
Phase 3 • Sponsor: Prof. Dr. med. Claus Rödel • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Can a short burst of radiation plus triple chemotherapy wipe out rectal cancer before surgery?
Cure OngoingThis phase 2 trial is testing whether a short course of radiation followed by a powerful three-drug chemotherapy regimen (FOLFOXIRI) can completely eliminate tumors in people with locally advanced rectal cancer before they undergo surgery. The study enrolls adults aged 18 to 70 w…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Cure
Last updated Jul 26, 2026 00:00 UTC
-
Radiation and chemo may spare rectal cancer patients from surgery
Cure OngoingThis study looks at whether a combination of radiation and chemotherapy can cure low rectal cancer, allowing patients to avoid surgery. About 108 people with early-stage rectal tumors near the anus will receive this treatment. The main goal is to see if the cancer stays under con…
Sponsor: Vejle Hospital • Aim: Cure
Last updated Jun 27, 2026 08:09 UTC
-
Could a vaccine stop colon cancer before it starts?
Vaccine OngoingThis study tests a vaccine that helps the body's immune system recognize and attack advanced colon polyps, which can turn into cancer. About 110 people who have had these polyps removed will receive either the vaccine or a placebo. The goal is to see if the vaccine boosts immune …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Vaccine
Last updated Sep 13, 2026 00:00 UTC
-
One patient keeps receiving experimental colorectal cancer drug pair
Disease control Expanded access (ended)This expanded access program provides continued treatment with CA102N plus lonsurf to a single patient with advanced or metastatic colorectal cancer. The patient had already completed at least 12 cycles of the same combination in an earlier clinical study. Expanded access allows …
Sponsor: Holy Stone Healthcare Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a hyaluronic acid drug combo outperform bevacizumab in Hard-to-Treat colon cancer?
Disease control PausedResearchers are testing whether adding an experimental drug called CA102N to the chemotherapy TAS-102 helps control metastatic colorectal cancer better than adding bevacizumab to TAS-102. The trial enrolls about 100 adults whose cancer has grown after standard chemotherapy. Parti…
Phase 2 • Sponsor: Holy Stone Healthcare Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a simpler scope technique match the complex one for large colon growths?
Disease control OngoingResearchers compare two ways to remove large, non-cancerous growths from the colon. One method, endoscopic mucosal resection, removes the growth in pieces. The other, endoscopic submucosal dissection, removes it in one piece but takes longer and carries more risk. The trial tests…
Sponsor: José Carlos Marín Gabriel • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immune cells take on tough tumors in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…
Phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug combo enters human testing
Disease control OngoingThis early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Robot-Assisted colonoscopy: a safer scope?
Disease control OngoingThis study will test a new robotic device called the Triton 1.5 System for performing colonoscopies, which are exams to look for colon cancer. About 40 adults who need a routine colonoscopy will take part. The main goal is to see if the robot is safe and can successfully complete…
Sponsor: Neptune Medical • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill takes on rare salivary gland and colon cancers
Disease control OngoingThis early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to c…
Phase 1 • Sponsor: Rgenta Therapeutics Inc • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase 1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Virus therapy joins Chemo-Radiation in fight against rectal cancer
Disease control OngoingThis early-phase trial tests a new treatment called NG-350A, a virus designed to stimulate the immune system inside tumors, combined with standard chemoradiotherapy for people with locally advanced rectal cancer. The study aims to see if this combination can improve the chance of…
Phase 1 • Sponsor: Akamis Bio • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail shows promise in early cancer trial
Disease control OngoingThis phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a shorter radiation course beat anal cancer?
Disease control By invitation onlyThis phase 2 trial is testing whether a shorter course of radiation therapy, given alongside standard chemotherapy, can effectively treat high-risk anal cancer. The standard treatment typically requires about 6 weeks of daily radiation, which can be a heavy burden for patients. T…
Phase 2 • Sponsor: University of Vermont Medical Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Blood test could guide stronger chemo for colon cancer
Disease control OngoingResearchers are testing whether a blood test that detects tiny amounts of tumor DNA can guide chemotherapy after surgery for early colon cancer. The trial compares two chemotherapy regimens: an intensive one called FOLFOXIRI and a standard one called CAPOX. They want to see if th…
Phase 2 • Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug targets Sugar-Coated proteins on cancer cells
Disease control OngoingResearchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…
Phase 1 • Sponsor: Phost'In Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New radiation boost may improve rectal cancer treatment
Disease control OngoingThis study tests whether giving a higher, targeted radiation dose to the main tumor and nearby lymph nodes can improve outcomes for people with locally advanced rectal cancer. About 128 adults whose cancer has not spread beyond the pelvis will receive either standard radiation or…
Phase 3 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New antibody aims to preserve immune checkpoint while fighting cancer
Disease control OngoingResearchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…
Phase 1/2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise in battling recurrent ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could less be more? new trial tests gentler treatment for anal cancer
Disease control OngoingThis phase II trial is testing whether a lower dose of chemotherapy plus radiation can work as well as the standard dose for early-stage anal cancer. The study includes 252 adults with T1-2N0M0 anal cancer. The goal is to see if the gentler approach controls the disease while imp…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for certain colorectal cancers
Disease control OngoingThis trial is testing whether giving the immunotherapy drug pembrolizumab before surgery can improve outcomes for people with high-risk stage 2 or stage 3 colorectal cancer that has a specific genetic feature called mismatch repair deficiency. About 88 participants will receive p…
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy aims to fight metastatic anal cancer
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin and paclitaxel) helps people with metastatic anal cancer live longer without their disease getting worse. About 205 adults with inoperable or recurrent anal cancer …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Dual-Action antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Immune-Boosting drug takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…
Phase 1 • Sponsor: Tizona Therapeutics, Inc • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
Disease control CancelledThis phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …
Phase 1/2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug JZP815 targets tough cancers in early trial
Disease control OngoingThis early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…
Phase 1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Immunotherapy after Chemo-Radiation may keep anal cancer at bay
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug nivolumab after standard combined modality therapy (chemo and radiation) can improve outcomes for patients with high-risk stage IIB-IIIC anal cancer. About 344 participants will receive nivolumab or a placebo. The m…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New device aims to prevent leaks after colon cancer surgery
Disease control OngoingThis study tests a device called ColoSeal ICD that is placed inside the colon after surgery to divert stool away from the surgical connection. The goal is to see if it is safe and feasible in 90 adults with rectal or rectosigmoid cancer. The device stays in place for about 10 day…
Sponsor: Averto Medical, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for certain cancers
Disease control OngoingThis study tests whether giving immunotherapy before surgery can help people with MSI/dMMR tumors. The goal is to shrink or eliminate the tumor before it is removed, potentially improving survival. The trial includes adults with localized, resectable cancers such as colorectal, g…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Experimental drug combo aims to tackle tough colorectal cancer
Disease control OngoingThis Phase 2 study tests whether adding leronlimab to standard chemotherapy and a targeted drug can shrink tumors or improve survival in people with a specific type of advanced colorectal cancer (MSS mCRC) that has not responded to prior treatments. About 66 adults will receive o…
Phase 2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Personalized dosing of cancer drug pazopanib tested in early trial
Disease control OngoingThis phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a malaria drug help fight cancer? early trial tests new combo
Disease control OngoingThis early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Targeted drug shows promise for Hard-to-Treat brain and bile duct cancers
Disease control OngoingThis study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Blood test could catch colon Cancer's return before it starts
Disease control OngoingThis study looks at whether a simple blood test can find tiny bits of cancer DNA left after surgery and chemotherapy for stage III colon cancer. If the test is positive, patients may get extra treatment with chemotherapy or immunotherapy to try to wipe out any remaining cancer ce…
Phase 3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Second chance: blood test guides retreatment for tough colorectal cancer
Disease control OngoingThis study is for people with a certain genetic type of advanced colorectal cancer (BRAF V600E) who previously benefited from a specific drug combination (encorafenib plus cetuximab). Researchers want to see if giving these drugs again, guided by a blood test that looks for cance…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill combo aims to tame Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: immunotherapy combo under trial
Disease control OngoingThis phase III trial compares two first-line treatments for people with a specific genetic subtype of metastatic colorectal cancer (dMMR/MSI-H). One group receives the immunotherapy drug atezolizumab alone, while the other gets atezolizumab combined with chemotherapy (FOLFOX) and…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…
Phase 1/2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new drug duo shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial tests an experimental drug called ONO-4578, both on its own and together with another experimental drug, ONO-4538, in people with advanced or metastatic solid tumors. The study also includes separate groups for people with gastric cancer or colorectal cance…
Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Personalized cancer attack: new trial matches drugs to tumor genes
Disease control OngoingThis phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo shows promise for hard-to-treat HER2 cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a radioactive drug seek out and attack solid tumors?
Disease control OngoingThis early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…
Phase 1 • Sponsor: Monopar Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can an antimalarial drug boost immunotherapy against colorectal cancer?
Disease control OngoingThis trial tests whether adding dihydroartemisinin, a malaria drug, to a standard chemotherapy plus immunotherapy combo can shrink or eliminate colorectal tumors in people whose cancer has not spread widely or has returned after first-line treatment. The goal is to make surgery m…
Phase 2 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can an immunotherapy cocktail make rectal tumors disappear before surgery?
Disease control OngoingThis phase 2 trial tests whether giving pembrolizumab, bevacizumab, and chemotherapy before surgery can improve outcomes for people with a common type of locally advanced rectal cancer. The cancer must be microsatellite stable, which typically does not respond well to immunothera…
Phase 2 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New cancer drug saruparib enters early human testing
Disease control OngoingThis early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control OngoingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Three-Drug chemo may let some rectal cancer patients skip surgery
Disease control OngoingThis phase II trial compares a three-drug chemotherapy combination (FOLFIRINOX) against standard two-drug combos (FOLFOX or CAPOX) in 783 patients with locally advanced rectal cancer. The goal is to see if the stronger regimen leads to a complete disappearance of the tumor, poten…
Phase 2/3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new gemcitabine formulation outsmart advanced solid tumors?
Disease control OngoingThis phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New liposome chemo shows promise in early cancer trial
Disease control OngoingThis early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a cocktail of immune boosters shrink Hard-to-Treat tumors?
Disease control OngoingThis phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can engineered immune cells tackle Hard-to-Treat KRAS cancers?
Disease control CancelledThis phase 1 trial tests an experimental cell therapy called IX001 TCR-T in adults with advanced pancreatic or colorectal cancer that has not responded to at least two standard treatments. The therapy uses a patient's own immune cells, engineered to recognize cancer cells with KR…
Phase 1 • Sponsor: Shanghai Pudong Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
Disease control OngoingThis phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…
Phase 1/2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New cocktail aims to outsmart resistant colorectal cancer
Disease control OngoingThis early-phase trial is testing a combination of chemotherapy (FOLFOX), an anti-angiogenic drug (bevacizumab), and two immunotherapies (botensilimab and balstilimab) in 20 patients with MSS metastatic colorectal cancer, a type that usually doesn't respond to immunotherapy. The …
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for…
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat cancers with BRAF mutation
Disease control OngoingThis early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for rare tumors: tarlatamab trial opens
Disease control OngoingThis study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Cancer drug brigimadlin tested for Long-Term use in solid tumour patients
Disease control OngoingThis study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for tough colon cancer: Triple-Drug attack shows promise
Disease control OngoingThis study tests a combination of three drugs (botensilimab, balstilimab, and regorafenib) in people with a type of advanced colorectal cancer that is hard to treat (MSS type) and has worsened after standard chemotherapy. The goal is to see if this mix can shrink tumors or slow t…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a smart drug deliver a One-Two punch to advanced cancers?
Disease control PausedThis trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …
Phase 1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug duo aims to shrink hard-to-treat tumors
Disease control OngoingThis early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill combo takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Diet and exercise may keep cancer patients stronger during chemo
Disease control OngoingThis study tests whether early, personalized nutritional support and a simple home exercise program can prevent weight loss and improve quality of life in 200 adults with lung, colorectal, ovarian, or pancreatic cancer starting palliative chemotherapy. Participants receive guidan…
Sponsor: Gødstrup Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New triple therapy targets Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and s…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New immunotherapy shows promise against multiple advanced cancers
Disease control OngoingThis study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new drug DM001 take on advanced solid tumors?
Disease control OngoingThis early-stage trial tests an experimental drug called DM001 in people with advanced solid tumors, including breast cancer, non-small cell lung cancer, and other solid cancers that have progressed on standard treatment. The main goals are to find a safe dose, identify side effe…
Phase 1 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New vaccine aims to stop colorectal cancer recurrence in High-Risk patients
Disease control OngoingThis study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…
Phase 2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cancer drug safety tracked in ongoing rollover trial
Disease control By invitation onlyThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a simple shot replace IV drips for some cancer patients?
Disease control OngoingThis early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Major trial pits two drug cocktails against Hard-to-Treat cancers
Disease control OngoingThis study compares two drug combinations for people with advanced neuroendocrine tumors (carcinoid cancer) that cannot be removed by surgery. Participants receive either octreotide plus interferon or octreotide plus bevacizumab. The goal is to see which combination better slows …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase 1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
Disease control OngoingThis early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …
Phase 1/2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Immunotherapy plus radiation may eliminate rectal cancer before surgery
Disease control OngoingThis study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can completely eliminate advanced rectal cancer before surgery. About 31 adults with a specific genetic type (MSI-H/dMMR) of stage II or III rectal cancer wil…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New pill takes on tough cancers in first human test
Disease control OngoingThis early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…
Phase 1 • Sponsor: Circle Pharma • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Cancer drug regorafenib gets a second chance in small continuation study
Disease control OngoingThis study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug dostarlimab shows promise in early trial for advanced cancers
Disease control OngoingThis early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…
Phase 1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug targets rare gene fusions in multiple cancers
Disease control OngoingThis phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Dual-Action drug outsmart advanced cancers?
Disease control OngoingThis early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…
Phase 1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New cocktail of drugs tested for Tough-to-Treat colon cancer
Disease control PausedThis phase 2 trial is testing whether a combination of four drugs—BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab—can help control advanced colorectal cancer that has not responded to standard treatments. The study is for people with a specific type called microsat…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug targets hard-to-treat cancer mutation in early trial
Disease control OngoingThis early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not …
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can changing the order of rectal cancer treatment boost survival?
Disease control OngoingThis trial tests whether giving chemotherapy before or after standard chemoradiation improves outcomes for people with locally advanced rectal cancer. Participants receive either the standard approach (chemoradiation, surgery, then chemo) or a total neoadjuvant therapy approach w…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
Disease control By invitation onlyThis extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …
Phase 3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Could a simple injection before and after surgery keep colorectal cancer at bay?
Disease control OngoingThis study tests whether a drug called QBECO, given as a self-injection before and after liver surgery, can lower the chance of colorectal cancer coming back or spreading. About 115 adults with colorectal cancer that has spread to the liver will take part. They will inject the dr…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Experimental drug combo targets Hard-to-Treat GI cancers
Disease control OngoingThis trial tests a new drug called BAY 1895344 (elimusertib) combined with standard chemotherapy (FOLFIRI) in people with advanced or metastatic stomach or colorectal cancer. The goal is to find the safest dose and see if the combination can shrink tumors. Participants receive th…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can aggressive tumor removal boost survival in Multi-Organ colorectal cancer?
Disease control OngoingThis trial asks whether adding maximal tumor debulking—removing or destroying as many metastases as possible through surgery, heat ablation, chemo-embolization, or targeted radiation—to standard chemotherapy improves overall survival in people with colorectal cancer that has spre…
Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Immunotherapy combo shows promise against Hard-to-Treat colorectal cancer
Disease control OngoingThis phase 3 trial compares two immunotherapy drugs (nivolumab alone or with ipilimumab) against standard chemotherapy in 839 people with a specific genetic type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see if the immunotherapies work better at stopping cancer g…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…
Phase 1/2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Cancer patients to continue promising treatments in major extension trial
Disease control By invitation onlyThis long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Cancer drug ruxolitinib keeps flowing to stable patients in rollover trial
Disease control OngoingThis study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, …
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
Disease control OngoingThis phase 2 trial is testing whether adding the immunotherapy drug durvalumab to the usual chemotherapy and radiation treatment can help people with locally advanced anal cancer stay cancer-free longer. The study includes about 180 adults with stage IIB–IIIC anal cancer. Partici…
Phase 2 • Sponsor: Goethe University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Cancer drug pertuzumab tested for Long-Term use in extension trial
Disease control OngoingThis study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill shrink advanced tumors? a new drug steps into the spotlight
Disease control OngoingThis early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a walking routine alter cancer biomarkers? new trial investigates
Disease control OngoingThis study explores whether regular aerobic exercise, specifically walking about 300 minutes per week, can change certain biomarkers in the blood that are linked to cancer risk. Participants are adults who have completed all cancer therapy and have either clonal hematopoiesis (a …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Light-Activated therapy could offer Surgery-Free route for early anal cancer
Disease control CancelledThis early-phase trial is testing whether a light-activated treatment, called photodynamic therapy (PDT), combined with vitamin D3, can safely treat high-grade anal dysplasia and very early anal cancer. Participants receive a photosensitizing drug that makes abnormal cells sensit…
Phase 1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a genetic marker make rectal cancer treatment more precise?
Disease control OngoingThis trial is testing whether a combination of chemotherapy drugs (liposomal irinotecan and capecitabine) plus radiation, given before surgery, can help people with locally advanced rectal cancer. The treatment plan is personalized based on a genetic marker (UGT1A1) that affects …
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant colorectal cancer?
Disease control CancelledThis trial is testing whether combining two standard drugs—fruquintinib and TAS-102—can help people with metastatic colorectal cancer that has stopped responding to at least two prior chemotherapy regimens. The study will measure how long patients live without the disease getting…
Sponsor: Fudan University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a targeted radiation combo boost rectal cancer remission?
Disease control PausedThis trial is testing whether a more focused radiation field, combined with chemotherapy and an immunotherapy drug called camrelizumab, can improve outcomes for people with a certain type of locally advanced rectal cancer. The study will compare this new approach to a standard tr…
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple therapy shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests whether adding two targeted drugs (encorafenib and cetuximab) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with a specific genetic type of advanced colorectal cancer. About 107 participants with untreated, metastatic …
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
Disease control OngoingThis trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …
Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Cancer drug spartalizumab gets extended safety check in ongoing patients
Disease control OngoingThis study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: liquid biopsy guides smarter drug choice
Disease control OngoingThis study looks at people with advanced colorectal cancer whose tumor tissue shows no RAS/BRAF mutation, but a liquid biopsy (blood test) finds a RAS mutation. It compares two standard drug combos (FOLFIRI plus either cetuximab or bevacizumab) to see which works better at stoppi…
Phase 3 • Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Robot arm takes on colon polyps: new study tests less invasive removal
Disease control OngoingThis study is testing a robotic device that doctors use through the anus to remove benign growths (polyps, adenomas) from the rectum and sigmoid colon. The goal is to see if the device can remove the entire growth in one piece safely, without causing bleeding or a hole in the bow…
Sponsor: EndoQuest Robotics, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Exercise after chemo: new trial tests if running and walking can keep colorectal cancer at bay
Disease control OngoingThis study tests whether a structured endurance exercise program, like walking or cycling, after finishing chemotherapy can help prevent colorectal cancer from returning. About 92 patients who have completed adjuvant chemotherapy will be randomly assigned to either an exercise pr…
Sponsor: Austrian Breast & Colorectal Cancer Study Group • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests a drug called tisotumab vedotin, alone or with other cancer medicines, in people with advanced colorectal, lung, pancreatic, or head and neck cancers that have stopped responding to standard treatments. About 350 participants receive different dosing schedules to…
Phase 2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a new drug ST316 shrink Hard-to-Treat tumors?
Disease control OngoingThis trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…
Phase 1 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Immunotherapy before surgery may help remove stubborn colon cancer
Disease control OngoingThis trial tests whether giving the immunotherapy drug camrelizumab before surgery can help completely remove T4 colon cancers that have a specific genetic feature (dMMR). These cancers often don't respond well to standard chemotherapy. The study will enroll 18 adults who will re…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer?
Disease control OngoingThis phase 3 trial tests whether a new drug combination (XL092 plus atezolizumab) works better than the current standard drug regorafenib for people with advanced colorectal cancer that has not responded to other treatments. About 900 participants will receive either the new comb…
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could your own gut bacteria restore bowel control after cancer surgery?
Disease control OngoingThis study tests whether transplanting a person's own fecal bacteria into the bowel before ileostomy reversal can improve bowel and anal function after rectal cancer surgery. Participants receive four weekly enemas made from their own stool. The goal is to reduce symptoms like le…
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug SHR-A2009 takes first steps against Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Adding a Blood-Vessel blocker to maintenance chemo may extend control of advanced colorectal cancer
Disease control OngoingThis phase 3 trial tests whether adding bevacizumab (a drug that starves tumors by blocking new blood vessels) to standard maintenance chemotherapy helps people with metastatic colorectal cancer stay progression-free longer. About 400 adults whose disease is controlled after 4–6 …
Phase 3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could fewer dressing changes be safer? trial tests biweekly PICC care for chemo patients
Disease control By invitation onlyThis trial compares changing the dressing on a PICC line (a type of central catheter) every week versus every two weeks in people with colon or pancreas cancer receiving chemotherapy. The goal is to see if less frequent changes are just as safe, with no increase in skin injuries,…
Sponsor: Institut Català d'Oncologia • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
Disease control OngoingThis phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…
Phase 1 • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo aims to tackle Chemotherapy-Resistant colorectal cancer in the abdomen
Disease control OngoingThis trial investigates whether combining two drugs—galunisertib and capecitabine—can help people with advanced colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases) and no longer responds to standard chemotherapy. The study has two parts: first, …
Phase 1/2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…
Phase 1/2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Digital assistant aims to close gaps in hereditary cancer care
Disease control By invitation onlyThis trial tests a digital tool that helps doctors and patients manage cancer risks linked to hereditary syndromes like BRCA-related breast/ovarian cancer and Lynch syndrome. The tool provides personalized recommendations during primary care visits. Researchers compare care gaps,…
Sponsor: HealthPartners Institute • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug shows promise against multiple Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Phase 1/2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at multiple Hard-to-Treat cancers
Disease control CancelledThis study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Timing of chemo may boost rectal cancer remission
Disease control OngoingThis trial tests whether giving chemotherapy before or after radiation therapy works better for people with locally advanced rectal cancer that has a high risk of coming back. Participants receive the same drugs (capecitabine and oxaliplatin) but in a different order. The goal is…
Phase 2 • Sponsor: Institute of Oncology Ljubljana • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Engineered virus joins forces with immunotherapy to fight resistant cancers
Disease control OngoingThis phase 2 trial tests whether a modified virus (VV1) combined with the immunotherapy drug cemiplimab can shrink tumors in people with colorectal cancer, head and neck squamous cell carcinoma, or melanoma that has stopped responding to checkpoint inhibitor treatment. The virus …
Phase 2 • Sponsor: Vyriad, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental drug COH29 targets tumor growth enzyme in advanced cancers
Disease control OngoingThis early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Immune-boosting combo aims to wipe out rectal cancer before surgery
Disease control OngoingThis study tests whether adding an immunotherapy drug (tislelizumab) to standard chemoradiation before surgery can improve outcomes for people with locally advanced rectal cancer. About 100 participants will receive the combination treatment, and researchers will measure how many…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug cocktail aims to shrink rectal tumors and avoid colostomy
Disease control OngoingThis study tests whether adding two drugs—adebrelimab (an immunotherapy) and apatinib (a targeted therapy)—to standard chemoradiotherapy before surgery can improve outcomes for people with locally advanced or low-lying rectal cancer. The goal is to shrink the tumor enough to allo…
Phase 2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Cancer patients get continued access to key therapy in extension study
Disease control OngoingThis study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Supercharged immune cells take aim at childhood cancers
Disease control OngoingThis study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
Disease control By invitation onlyThis clinical trial is testing whether combining two drugs—capecitabine (a chemotherapy pill) and lenvatinib (a targeted therapy)—can shrink tumors in people with advanced colorectal cancer that has stopped responding to standard treatments. The study enrolls adults aged 19 and o…
Phase 1/2 • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with PI3K mutation
Disease control OngoingThis early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…
Phase 1 • Sponsor: OnKure, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New cancer combo aims to shrink Hard-to-Treat tumors
Disease control OngoingThis study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to spare lymph nodes and boost rectal cancer outcomes
Disease control OngoingThis Phase III trial tests whether a modified short-course radiation that spares nearby lymph nodes, combined with chemotherapy (CAPOX) and the immunotherapy drug tislelizumab, works better than standard radiation plus chemotherapy for people with a certain type of rectal cancer …
Phase 3 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Cancer drug safety tracked over years in ongoing study
Disease control OngoingThis study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can early rectal cancer be treated without removing the rectum?
Disease control OngoingThis trial investigates whether less invasive treatments can save the rectum in people with early-stage rectal cancer. Participants receive either standard surgery (removing part of the rectum) or one of two organ-sparing approaches: short-course radiotherapy or chemoradiation (c…
Phase 2/3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase 2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant cancers
Disease control OngoingThis early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New triple therapy aims to wipe out rectal cancer before surgery
Disease control OngoingThis phase II trial is testing whether adding an experimental immunotherapy drug (retlirafusp alfa) to short-course radiation and standard chemotherapy can completely eliminate locally advanced rectal cancer before surgery. The study plans to enroll 44 adults aged 18-70 with stag…
Phase 2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Diet study hopes to boost survival in colorectal cancer patients
Disease control OngoingThis study tests whether following the Norwegian dietary guidelines—including healthy foods, cooking classes, and physical activity—can improve survival and reduce cancer recurrence in 503 people who had colorectal cancer. Participants are guided by nutritionists and given food d…
Sponsor: University of Oslo • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…
Phase 1 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Glowing dye could help surgeons spot hidden cancer during colorectal surgery
Disease control By invitation onlyThis trial investigates whether using a special dye called indocyanine green (ICG) during surgery helps improve outcomes for people with stage III colorectal cancer. The dye makes lymph nodes and cancer tissue glow under a special camera, helping surgeons see and remove more of t…
Sponsor: Shanghai Tong Ren Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cocktail aims to shrink Hard-to-Treat colon tumors
Disease control OngoingThis phase 2 trial is testing a combination of three drugs—ATRA (a vitamin A derivative), bevacizumab (a blood vessel growth blocker), and atezolizumab (an immunotherapy)—in 22 people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see i…
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered virus targets Hard-to-Treat cancers in early trial
Disease control By invitation onlyThis early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…
Early phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…
Phase 1/2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to control advanced colon cancer
Disease control OngoingThis study tests two drugs—regorafenib (a chemotherapy pill) and pembrolizumab (an immunotherapy)—in people with metastatic colorectal cancer who have already tried several other treatments. The goal is to see if the combination is safe and can slow tumor growth. About 73 partici…
Phase 1/2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo attack targets hard-to-treat KRAS G12C cancers
Disease control OngoingThis study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a daily aspirin keep colon cancer from returning?
Disease control OngoingThis phase 3 trial tests whether taking a low-dose aspirin (100 mg) daily for three years can prevent colon cancer from coming back after surgery. It includes 264 people with stage II or III colon cancer who have a specific mutation in the PI3K gene. Participants are randomly ass…
Phase 3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests whether a combination of two targeted drugs (encorafenib and cetuximab), given alone or with chemotherapy, works better than standard chemotherapy for people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation) that has spread and hasn…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Fasting diet may boost recovery after colon cancer surgery
Disease control OngoingThis study is testing whether a short-term, low-calorie diet called a fasting mimicking diet (FMD) can help patients recover better after surgery for colorectal cancer. The diet is given in cycles after the operation and is designed to be easier to follow than complete fasting. R…
Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug AZD9592 enters first human trials for tough cancers
Disease control OngoingThis early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could chemo replace surgery for rectal cancer? new study explores
Disease control OngoingThis study tests whether a combination of chemotherapy (FOLFOX) and a short course of radiation can eliminate advanced rectal cancer without needing surgery. 12 adults with locally advanced rectal cancer are being watched closely after treatment to see if the cancer fully respond…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Immune cell therapy shows promise for tough cancers
Disease control OngoingThis phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…
Phase 2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Robot-Assisted surgery for colon tumors under study
Disease control OngoingThis study looks at how well a new robotic surgical system works for removing colon or rectal tumors. About 60 adults who need surgery for benign or malignant colorectal conditions will take part. The goal is to see if the system is safe and can complete the surgery without switc…
Sponsor: Intuitive Surgical • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Liver-Directed chemo may shrink tumors enough for surgery in colorectal cancer
Disease control OngoingThis phase II trial tests whether delivering chemotherapy directly into the liver (hepatic arterial infusion) along with standard IV chemo can shrink inoperable liver tumors from colorectal cancer enough to allow surgical removal. The study involves 64 participants whose cancer h…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can simple tools help cancer survivors live healthier?
Disease control OngoingThis study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New immune therapy aims to train body to attack rectal cancer cells
Disease control OngoingThis early phase trial tests a biological product mix designed to train the immune system to recognize and kill CEA-positive rectal cancer cells. The study involves 20 participants with early-stage rectal cancer (Stage 0 to IIA) who have not yet developed symptoms or metastasis. …
Phase 1 • Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThis study tests whether a single immunotherapy drug, dostarlimab, can effectively treat people with a specific type of advanced rectal cancer (dMMR/MSI-H) that has not been treated before. About 154 participants will receive the drug and, if their cancer completely disappears, t…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New chemo cocktail shows promise for tough-to-treat colorectal cancer
Disease control OngoingThis study tests a more intense chemotherapy regimen (mFOLFOXIRI) plus the drug bevacizumab against a standard regimen (mFOLFOX-6) plus bevacizumab as a first treatment for people with advanced colorectal cancer that cannot be removed by surgery. The trial includes 528 participan…
Phase 3 • Sponsor: Yanhong Deng • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Timing of chemo could be key in colon cancer fight
Disease control OngoingThis study looks at whether giving chemotherapy both before and after surgery (perioperative) is better than only after surgery for people with advanced colon cancer. About 738 participants will be randomly assigned to one of two groups. The goal is to see if the perioperative ap…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Immunotherapy combo shows promise in shrinking colorectal tumors before surgery
Disease control OngoingThis phase 2 pilot study is testing whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery can shrink tumors in people with colorectal cancer. The trial includes 26 participants across three groups, with some receiving more doses and one group having…
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to shrink rectal tumors before surgery
Disease control OngoingThis study tests whether combining two drugs (nivolumab and regorafenib) with short-course radiation can shrink tumors in people with stage II or III rectal cancer. About 72 participants will receive the drugs before and after radiation, followed by surgery or a watch-and-wait ap…
Phase 2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug cocktail aims to tame advanced colon cancer
Disease control OngoingThis study is testing whether a combination of three drugs—trifluridine/tipiracil, capecitabine, and bevacizumab—can safely control metastatic colorectal cancer in people who are not healthy enough for standard intensive chemotherapy. The first part finds the best dose, and the s…
Phase 1/2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Virus-Immunotherapy cocktail takes on tough GI cancers
Disease control OngoingThis early-stage trial is testing a combination of pelareorep (a reovirus) and atezolizumab (an immunotherapy) along with standard chemotherapies in people with advanced anal or pancreatic cancers. The study aims to find safe doses, look for biomarkers that predict response, and …
Phase 1/2 • Sponsor: Oncolytics Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Virus therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…
Phase 1 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Zapping cancer during surgery: new rectal cancer trial underway
Disease control OngoingThis study tests whether giving a single dose of radiation directly to the tumor area during surgery is feasible for people with advanced or recurrent rectal cancer. About 31 participants will be randomly assigned to receive standard surgery, surgery plus a standard radiation dos…
Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug duo aims to outsmart stubborn cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail targets Hard-to-Treat colorectal cancer mutation
Disease control By invitation onlyThis study tests two drug combinations for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. In one group, patients who haven't had treatment yet will receive the drugs IBI351 and cetuximab β plus chemotherapy (FOLFIRI). In another group,…
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Phase 1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo treatment may slow colorectal cancer spread
Disease control OngoingThis trial is for people with colorectal cancer that has spread to a few spots in the body but cannot be fully removed by surgery alone. After 3-4 months of standard chemotherapy, participants either continue chemotherapy alone or also receive local ablative therapy—such as surge…
Sponsor: Australasian Gastro-Intestinal Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Universal CAR-T therapy takes on advanced colorectal cancer
Disease control PausedThis early-phase trial tests a new universal CAR-T cell therapy (REVO-UWD-01) in 30 adults with metastatic colorectal cancer that has spread. The treatment targets a protein called GCC found on cancer cells. The main goals are to find the safest dose and check for side effects, w…
Early phase 1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Short radiation plus chemo before surgery may boost rectal cancer survival
Disease control OngoingThis phase 3 trial compares two treatment approaches for high-risk rectal cancer. The experimental group gets a short course of radiation (5 days) followed by several months of chemotherapy before surgery. The standard group receives longer chemoradiotherapy followed by surgery a…
Phase 3 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can a Nurse-Led program transform Women's health in hong kong?
Disease control OngoingThis trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New device could help colon cancer patients avoid a stoma bag
Disease control By invitation onlyThis study tests a temporary device called Colovac that is placed inside the bowel after colon cancer surgery to protect the surgical connection. The goal is to see if it can help patients avoid needing a temporary stoma bag. About 108 adults with colon cancer will take part, and…
Sponsor: SafeHeal Inc • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Electric bandage aims to zap surgical infections
Disease control By invitation onlyThis study tests whether a bioelectric wound dressing can reduce infections after colon surgery better than the usual antiseptic skin prep. About 20 adults having elective colon surgery will be enrolled. Researchers will measure bacteria levels in skin samples to compare the two …
Sponsor: AdventHealth • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New rectal cancer device tested in elderly patients
Disease control PausedThis pilot study tests a new rectal applicator for delivering radiation therapy to elderly patients with inoperable rectal cancer. The treatment combines external beam radiation with three sessions of internal radiation (brachytherapy) using the new device. The study aims to see …
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a tiny dose of immunotherapy tame tough cancers?
Disease control By invitation onlyThis study tests a low dose of the immunotherapy drug nivolumab, alone or with chemotherapy, in people with advanced colorectal or stomach cancers that have a specific genetic feature (MSI/dMMR). The goal is to see if this approach can shrink tumors before surgery or control the …
Phase 2 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to shrink hard-to-treat GI tumors
Disease control OngoingThis study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo tested for advanced cancers
Disease control OngoingThis early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Could a lower dose of immunotherapy shrink colorectal tumors before surgery?
Disease control OngoingThis phase 2 trial is testing whether low doses of the immunotherapy drugs nivolumab or pembrolizumab can shrink tumors in people with a specific genetic type of colorectal cancer (MSI/dMMR) before they have surgery. The study involves 30 participants with stage II-III disease wh…
Phase 2 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for elderly colorectal cancer patients: triple therapy shows promise
Disease control OngoingThis study looks at how well a combination of three drugs—capecitabine, oxaliplatin, and bevacizumab—works as a first treatment for elderly patients (70 and older) with metastatic colorectal cancer that cannot be removed by surgery. The goal is to see if this approach can delay c…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Cancer patients get continued access to promising drug
Disease control OngoingThis study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a vitamin e boost chemo for advanced colon cancer?
Disease control OngoingThis phase II trial tests whether adding tocotrienol, a form of vitamin E, to standard chemotherapy and bevacizumab can improve treatment and reduce side effects in people with metastatic colorectal cancer. About 83 participants will be randomly assigned to receive either tocotri…
Phase 2 • Sponsor: Vejle Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy under observation for advanced colon cancer
Disease control OngoingThis study is observing 300 adults with metastatic colorectal cancer who are receiving a combination of two drugs (fluoropyrimidine and bevacizumab). The goal is to measure how long patients live and how long the cancer stays under control. The study is not testing a new treatmen…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could chemo around surgery beat cancer spread in the belly?
Disease control OngoingThis study tests whether giving chemotherapy before and after surgery (plus heated chemo directly into the abdomen) helps people with colorectal cancer that has spread to the lining of the abdomen live longer. About 358 adults with resectable disease are randomly assigned to eith…
Phase 2/3 • Sponsor: Koen Rovers • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests a new drug called JDQ443, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the drug can shrink tumors. About 344 adults whose cancer has not …
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Liver metastases showdown: radiation vs. microwave ablation in new trial
Disease control OngoingThis study compares two minimally invasive treatments—microwave ablation and stereotactic body radiation therapy—for colorectal cancer that has spread to the liver. About 100 patients with 1 to 3 liver tumors that cannot be surgically removed will be randomly assigned to one of t…
Phase 2 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can a daily aspirin help fight colorectal cancer? new trial targets genetic weakness
Disease control OngoingThis study tests whether low-dose aspirin can help prevent colorectal cancer from coming back in patients whose tumors have certain genetic changes (in the PI3K pathway). Over 600 patients who had surgery for stage II or III colon or rectal cancer are randomly assigned to take as…
Phase 3 • Sponsor: Anna Martling • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could vitamin D3 boost chemo for advanced colon cancer?
Disease control OngoingThis phase III trial tests whether adding high-dose vitamin D3 to standard chemotherapy and bevacizumab helps people with metastatic colorectal cancer. About 455 patients who have not had prior treatment for their advanced disease are taking part. The goal is to see if the vitami…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo targets tough cancers with RAS mutation
Disease control OngoingThis early-stage trial is testing whether a combination of two drugs, naporafenib and trametinib, can shrink or control advanced solid tumors that have a specific genetic change called RAS Q61X. About 86 people whose cancer has not responded to standard treatments will receive th…
Phase 1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Simple surgical stitch may prevent dangerous bowel blockage after rectal cancer surgery
Disease control OngoingThis study looks at whether closing the pelvic floor with stitches after removing rectal cancer can stop the bowel from getting blocked. About 516 people having keyhole surgery for mid-low rectal cancer will be randomly assigned to get the closure or not. The main goal is to see …
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Exercise after surgery may keep metastatic colorectal cancer at bay
Disease control OngoingThis study looks at whether a 6-month exercise program (a mix of aerobic and resistance training) can improve fitness and reduce the risk of cancer coming back in patients who had surgery for colorectal cancer that spread to the liver. About 66 participants will be split into thr…
Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New study aims to help cancer survivors manage other health problems
Disease control OngoingThis study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …
Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental cancer combo aims to supercharge immune attack on tumors
Disease control OngoingThis early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…
Phase 1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Blood-Guided chemo dosing study for colon cancer withdrawn
Disease control CancelledThis pilot study aimed to see if adjusting the dose of the chemotherapy drug 5-FU based on its concentration in the blood could improve treatment for metastatic colorectal cancer. The study was withdrawn before enrolling any participants. It was designed for adults with metastati…
Phase 2 • Sponsor: Inova Health Care Services • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can early chemo beat the clock against colon cancer?
Disease control OngoingThis study looks at whether starting chemotherapy 10 to 14 days after surgery for stage III colon cancer is better than waiting the usual 2 weeks or more. About 300 patients are taking part to see if earlier treatment improves survival and lowers the chance of cancer coming back.…
Phase 3 • Sponsor: Kyungpook National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…
Phase 1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Less invasive needle treatment could rival surgery for liver tumors
Disease control OngoingThis study compares two treatments for colorectal cancer that has spread to the liver: surgical removal of tumors versus a less invasive needle ablation procedure guided by 3D imaging. 230 patients are randomly assigned to one of the two treatments. The goal is to see if ablation…
Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo aims to cut rectal cancer treatment time and boost cure rates
Disease control OngoingThis Phase 2 trial tests a shorter course of radiation followed by FOLFOX chemotherapy before surgery for locally advanced rectal cancer. About 364 participants will be randomly assigned to either this new regimen or standard chemoradiation. The goal is to see if the shorter appr…
Phase 2 • Sponsor: Kyungpook National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Promising colorectal cancer study pulled before it even started
Disease control CancelledThis study aimed to see if adding the targeted drug inavolisib to standard chemotherapy and bevacizumab could help people with a specific genetic form of advanced colorectal cancer (PIK3CA-mutated). It was designed for adults who had not yet received treatment for metastatic dise…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New study aims to make complex pelvic cancer surgery safer
Disease control By invitation onlyThis study looks at standardizing the surgical process for patients with advanced or recurrent rectal cancer that has spread to nearby organs. The procedure, called pelvic exenteration, removes the tumor along with affected structures. The goal is to improve teamwork among surgeo…
Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Heated chemotherapy showdown: which works better for abdominal cancer spread?
Disease control OngoingThis study compares two ways of giving chemotherapy directly into the belly after surgery to remove visible cancer from the lining of the abdomen. The cancer comes from the appendix, colon, or rectum. About 292 adults will be randomly assigned to receive either early post-operati…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug duo aims to control colorectal cancer
Disease control OngoingThis small pilot study is testing two immunotherapy drugs, botensilimab and balstilimab, in 16 people with advanced colorectal cancer that has not spread to the liver. Participants receive the drugs in 6-week cycles, and if the cancer progresses, standard chemotherapy is added. T…
Phase 2 • Sponsor: Nicholas DeVito, MD • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
DNA-Guided chemo aims to stop colon cancer return
Disease control PausedThis study tests whether using a blood test for circulating tumor DNA (ctDNA) can help doctors decide if patients with stage II or III colon cancer need stronger chemotherapy after surgery. The trial compares standard chemo with a more intense regimen (FOLFOXIRI) and an additiona…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New program aims to close cancer screening gaps for rural families
Disease control By invitation onlyThis study tests a two-year follow-up program for 200 adults with hereditary cancer syndromes like BRCA or Lynch syndrome. Participants get personalized care plans and regular check-ins with a genetics doctor to help them follow cancer prevention and screening guidelines. The goa…
Sponsor: University of Vermont Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New pill targets aggressive tumors with genetic flaw
Disease control OngoingThis early-phase study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug works by blocking a protein (WRN) that these tumors need to survive. The study aims to see if the drug, alone or w…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy aims to skip radiation for rectal cancer patients
Disease control OngoingThis study tests a new approach for people with locally advanced rectal cancer that has a common genetic profile (MSS/pMMR). Instead of standard radiation before surgery, participants receive a combination of chemotherapy (mFOLFOX6) and an immunotherapy drug (PD-1 antibody). The …
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New Stitch-Free staple technique aims to cut leak risk in rectal cancer surgery
Disease control By invitation onlyThis trial tests a modified stapling technique (MST) against the standard method in 450 adults having minimally invasive rectal cancer surgery. The goal is to see if MST reduces the chance of anastomotic leaks, a serious complication. Participants will be randomly assigned to one…
Sponsor: Korea University Anam Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Phase 1/2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Supercharged immune cells take on advanced cancers
Disease control OngoingThis early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …
Phase 1 • Sponsor: AgonOx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo aims to outsmart stubborn colorectal cancer
Disease control OngoingThis phase 2 trial tests whether combining the immunotherapy nivolumab (Opdivo) with the chemotherapy oxaliplatin can help control or shrink metastatic colorectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS)—types that usually don't respond well…
Phase 2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug shows promise for rare lung cancer subtype
Disease control OngoingThis phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug duo shows promise for tough colorectal cancer
Disease control OngoingThis phase II trial is testing whether combining two drugs—niraparib and panitumumab—can help people with advanced colorectal cancer that has spread. The study includes 26 patients whose cancer has not responded to at least one prior treatment. The goal is to see if the combinati…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New study aims to find best method for removing Pre-Cancerous colon polyps
Disease control By invitation onlyThis study compares two methods for removing certain types of colon polyps (10-19mm adenomas or serrated lesions 10mm or larger) during a colonoscopy: cold snare piecemeal resection (CSPR) and cold snare endoscopic mucosal resection (Cold EMR). About 570 adults will take part to …
Sponsor: Indiana University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for advanced bowel cancer patients too frail for strong chemo
Disease control OngoingThis phase 3 study tests whether a combination of trifluridine/tipiracil (a chemotherapy pill) and bevacizumab (a targeted therapy) works better than the current standard of capecitabine plus bevacizumab for people with metastatic colorectal cancer who are not healthy enough for …
Phase 3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Less cutting, same cure? new trial tests smaller surgery for rectal cancer
Disease control OngoingThis study tests whether surgeons can safely remove less tissue during surgery for upper rectal cancer after patients have received pre-surgery therapy. About 874 adults with locally advanced rectal cancer will be randomly assigned to either standard or reduced surgical margins. …
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could less radiation be better for anal cancer? new trial aims to find out
Disease control OngoingThis study tests whether giving a lower dose of radiation to nearby lymph nodes can reduce side effects in people with anal cancer who are also receiving chemotherapy. The trial includes 33 adults with locally advanced anal cancer. The goal is to see if this approach lowers toxic…
Phase 2/3 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Keytruda shows promise in shrinking untreatable bowel tumors
Disease control OngoingThis phase 2 trial is testing the immunotherapy drug pembrolizumab (Keytruda) in 25 adults with a specific type of advanced colorectal cancer (dMMR) that cannot be surgically removed. The goal is to see if the drug can shrink the tumors enough to make surgery possible. Treatment …
Phase 2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy combo shows promise against tough colorectal cancer
Disease control OngoingThis Phase 2 trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery to 29 patients with a specific genetic type of colorectal cancer (MSI-H/dMMR). The goal is to see if this combination can completely eliminate the tumor before surgery. Researcher…
Phase 2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug combo aims to extend life in tough colorectal cancer
Disease control OngoingThis phase 3 trial tests whether combining regorafenib and irinotecan works better than regorafenib alone for people with metastatic colorectal cancer who have already tried standard treatments. About 377 participants will receive either the combo or the single drug. The main goa…
Phase 3 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Immunotherapy shows promise for untreated rectal cancer in chinese patients
Disease control OngoingThis study tests a drug called dostarlimab in 23 Chinese patients with a specific type of advanced rectal cancer (dMMR/MSI-H) that has not been treated before. The goal is to see if the drug can make the cancer disappear completely and stay gone for at least 12 months. Patients r…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental immunotherapy combo for tough colorectal cancer trial pulled before start
Disease control CancelledThis study was designed to test an experimental immunotherapy called AlloStim combined with a checkpoint inhibitor (avelumab) in people with advanced colorectal cancer that had stopped responding to multiple prior treatments. The trial was withdrawn before any participants were e…
Phase 2 • Sponsor: Mirror Biologics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New supplement aims to fight malnutrition in cancer patients
Disease control By invitation onlyThis study looks at whether a special drink made with easily digested protein and MCT oil can help improve malnutrition in cancer patients who are having radiotherapy. The study will follow 132 adults with head and neck, lung, rectal, or esophageal cancer for 12 weeks. Researcher…
Sponsor: Outcomes'10 • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Painkiller methadone joins chemo in fight against hard-to-treat colon cancer
Disease control OngoingThis early-phase trial tests whether adding the painkiller D,L-methadone to standard chemotherapy (mFOLFOX6) can help control advanced colorectal cancer that has stopped responding to other treatments. The study has two parts: first, finding a safe dose of methadone; second, comp…
Phase 1/2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New radiation approach may help rectal cancer patients avoid surgery
Disease control OngoingThis study tests whether a special type of internal radiation (contact X-ray brachytherapy) given after standard chemoradiation can help more people with early rectal cancer keep their rectum, compared to standard external beam radiation. About 148 adults with small, early-stage …
Phase 3 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Double-Barreled attack: chemo plus targeted liver beads tested for stubborn colon cancer spread
Disease control OngoingThis phase 2 trial is testing whether adding a liver-directed chemoembolization procedure to standard chemotherapy can better shrink tumors in people with colorectal cancer that has spread only to the liver and has a poor outlook. About 48 participants will receive either chemoth…
Phase 2 • Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can digital nutrition help cancer patients fight malnutrition?
Disease control OngoingThis study tests whether improved nutritional support, delivered through digital tools and personalized advice, can reduce malnutrition in cancer patients. Around 130 adults with gynecologic, colorectal, or lymphoma cancers will receive either standard dietary advice or enhanced …
Sponsor: University of Oslo • Aim: Disease control
Last updated Jun 26, 2026 14:40 UTC
-
Cancer combo trial pulled before it even started
Disease control CancelledThis study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC
-
New hope for Hard-to-Treat colorectal cancer: experimental drug combo enters human trials
Disease control By invitation onlyThis study tests a new oral drug called XS-03 combined with standard chemotherapy and a targeted antibody (bevacizumab) in 102 people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if the combination is safe and shrinks tumors better than current tr…
Phase 1/2 • Sponsor: NovaOnco Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 12:33 UTC
-
AI-Powered Low-Dose CT could spare cancer patients unnecessary radiation
Diagnosis OngoingThis study tests whether a low-radiation CT scan, enhanced with artificial intelligence software, can detect liver tumors as accurately as a standard CT scan. About 146 adults with colorectal cancer and known liver metastases will receive both scans. The goal is to see if the low…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
A new imaging agent aims to make solid tumors visible on PET scans
Diagnosis Expanded access (paused)This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…
Sponsor: Monopar Therapeutics • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Can a radioactive antibody light up hidden tumors on PET scans?
Diagnosis OngoingResearchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…
Phase 1 • Sponsor: Monopar Therapeutics • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
AI-Powered test aims to predict best cancer treatment for each patient
Diagnosis CancelledThis study tests a new platform called xDRIVE that combines drug sensitivity testing and AI to predict which treatments will work best for people with advanced colorectal cancer. The platform will not provide treatment itself but will give doctors a recommendation. The goal is to…
Sponsor: First Ascent Biomedical Inc. • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
New study aims to find the best way to catch HPV cancers early in HIV patients
Diagnosis OngoingThis study looks at which tests work best to find early signs of HPV-related cancer in the cervix or anus of people living with HIV. About 1,586 participants from Mexico and Puerto Rico will be tested using different methods, including HPV tests and cell samples. The goal is to c…
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Aug 26, 2026 00:00 UTC
-
Can new tracers make many cancers light up on scans?
Diagnosis OngoingThis early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…
Early phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis By invitation onlyThis trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new PET tracer spot tumors more clearly?
Diagnosis CancelledThis trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…
Sponsor: Jinling Hospital, China • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Better swab, better catch: study aims to sharpen anal cancer screening
Diagnosis OngoingThis study compares different ways to collect anal cell samples and different HPV tests to see which combination best predicts high-grade anal dysplasia, a pre-cancerous condition. Researchers are enrolling men who have sex with men, including those with and without HIV. The goal…
Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
New blood test could catch colon cancer before it spreads
Diagnosis OngoingThis study is developing a blood test that looks for specific DNA changes to find colorectal cancer early, even before symptoms appear. Researchers are analyzing blood samples from 500 people with and without cancer to see how accurate the test is. The goal is to create a simple,…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Blood test could revolutionize colon cancer screening
Diagnosis OngoingThis study is testing a new blood test called LUNAR-2 that looks for DNA from colorectal cancer in the bloodstream. It involves over 44,000 average-risk adults aged 45-84 who are already scheduled for a screening colonoscopy. The goal is to see how well this blood test can detect…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Could a simple stool test replace colonoscopy for cancer screening in cystic fibrosis?
Diagnosis OngoingThis study looks at whether stool-based tests (like the FIT test and Cologuard) can accurately detect colorectal cancer and precancerous polyps in adults with cystic fibrosis. Researchers will compare these non-invasive tests to the standard colonoscopy in 350 participants. The g…
Sponsor: University of Washington, the Collaborative Health Studies Coordinating Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
Could a simple mailed kit save more lives from colorectal cancer?
Diagnosis OngoingThis study tests whether sending a colorectal cancer screening test directly to people's homes, without needing to order it first, increases the number of people who get screened. It involves 64,000 adults aged 50-74 in France. The goal is to see if this simple change leads to mo…
Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
Simple blood test could transform cancer monitoring
Diagnosis OngoingThis study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…
Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
New stool test aims to improve colorectal cancer detection
Diagnosis PausedThis study aims to see how well a new stool test, called LifeKit Prevent, can detect colorectal cancer and precancerous growths (adenomas). About 12,000 adults aged 40 and older scheduled for a screening colonoscopy will provide a stool sample for the test. The results will be co…
Sponsor: Metabiomics Corp • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
Can diet and exercise programs cut cancer risk? new study tests lifestyle changes
Prevention OngoingThis study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…
Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can a vaccine stop GI cancers from returning?
Prevention PausedResearchers are testing an experimental vaccine called Ad5.F35-hGCC-PADRE in adults who have had surgery and standard treatment for gastrointestinal cancers, including pancreatic, colorectal, esophageal, gastric, and small bowel adenocarcinomas. The trial aims to find a safe dose…
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
50,000 veterans in landmark study to settle colonoscopy vs. stool test debate
Prevention OngoingThis large study compares two common colorectal cancer screening methods: colonoscopy and annual fecal immunochemical testing (FIT). Over 50,000 veterans aged 50-75 will be randomly assigned to one of the two screenings and followed for 10 years. The goal is to see which approach…
Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
Could a simple stool test spare thousands from repeat colonoscopies?
Prevention OngoingThis trial tests whether an annual stool-based test (FIT) can be as effective as routine colonoscopy for people who have had advanced polyps removed. Participants aged 50 to 65 from colorectal cancer screening programs will be randomly assigned to either yearly FIT or scheduled e…
Sponsor: Fundacin Biomedica Galicia Sur • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
Can beans beat obesity and colon cancer?
Prevention OngoingThis study tests whether a high-fiber diet centered on legumes like dry beans can help overweight or obese adults who have had colon polyps lose weight and reduce their risk of colon cancer. Participants follow a diet with pre-portioned meals for up to a year, with nutritionist s…
Sponsor: Emory University • Aim: Prevention
Last updated Aug 22, 2026 00:00 UTC
-
Can a simple text message save lives? new trial aims to boost colon cancer screening
Prevention By invitation onlyThis study tests whether sending text reminders to patients who are overdue for colorectal cancer screening helps them follow through and get a colonoscopy or stool test. About 3,888 adults with a scheduled primary care visit will take part. The goal is to make it easier for peop…
Sponsor: University of Pennsylvania • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
Diet study aims to cut colon cancer risk in overweight adults
Prevention OngoingThis study tests three different eating plans to see which helps overweight adults at risk for colorectal cancer eat healthier and lose weight. About 240 participants will follow one of the plans for 12 months, with support from phone calls and a phone app. The goal is to find be…
Sponsor: University of Michigan • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Can a common drug stop Chemo's nerve pain?
Prevention PausedThis phase II trial tests whether riluzole, a drug used for ALS, can prevent nerve damage caused by oxaliplatin chemotherapy in people with stage II/III colorectal cancer. About 80 participants will receive either riluzole or a placebo during their chemo. The study is currently s…
Phase 2 • Sponsor: UNICANCER • Aim: Prevention
Last updated Jun 27, 2026 12:35 UTC
-
Can a text message boost cancer screening rates?
Prevention OngoingThis study tests whether a mobile health tool called mPATH™-Cloud can help more people get screened for colorectal cancer. Over 1,000 patients from a community health center in North Carolina who are overdue for screening will either receive usual care or get a link to the tool, …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
Massive norwegian study aims to slash colon cancer deaths with simple screening
Prevention OngoingThis large study is testing whether a screening procedure called flexible sigmoidoscopy can lower the number of colorectal cancer cases and deaths. About 100,000 men and women aged 50-64 in Norway are taking part. The study also looks at adding a stool blood test and how screenin…
Sponsor: Norwegian Institute of Public Health • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
New hope: drug cocktail aims to stop colon cancer recurrence
Prevention OngoingThis study tests whether taking two drugs, eflornithine and sulindac, together can lower the chance of new high-risk growths or a second colon cancer in people who have already had stage 0 to III colon or rectal cancer. About 350 participants who are cancer-free after surgery wil…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
New tools aim to boost colonoscopy rates and prevent cancer
Prevention By invitation onlyThis study tests ways to help more people complete a colonoscopy after an abnormal stool-based colorectal cancer screening test. The researchers will use team-based best practices in clinics and a patient app with enhanced instructions and navigation. About 2,000 adults who speak…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
Rural cancer screening boost? new study tests provider tools
Prevention OngoingThis study tests a program called CARES-REACH that trains healthcare providers and uses electronic medical record tools to increase colorectal cancer screening rates in rural clinics. Researchers are working with 49 staff and providers from two healthcare systems. The goal is to …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Prevention
Last updated Jun 27, 2026 08:01 UTC
-
Mailed test kits aim to boost colon cancer screening in underserved brooklyn
Prevention By invitation onlyThis study tests whether sending a letter, a home stool test kit (FIT), and follow-up phone calls can increase colorectal cancer screening among 3,000 patients aged 45-75 at community health centers in Brooklyn. Those who respond get help completing the test or scheduling a colon…
Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 08:01 UTC
-
Daily aspirin may cut colon cancer risk, new study hints
Prevention OngoingThis study looked at whether taking a daily aspirin can reduce the risk of colorectal cancer in people who have already had a precancerous polyp (adenoma) removed. Researchers measured certain substances in urine and blood that are linked to inflammation and cancer growth. The go…
Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:01 UTC
-
Can surgeons spare nerves and still cure colon cancer?
Symptom relief OngoingDoctors remove right or left colon cancer along with nearby lymph nodes, but the deep nerves that control the gut often get damaged. That damage can leave patients with lasting diarrhea, bowel spasms, or slow bowel movements. This trial compares standard surgery with a laparoscop…
Sponsor: Fudan University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
A bag that holds the small intestine could change colon surgery
Symptom relief By invitation onlyDuring laparoscopic surgery on the rectum or lower sigmoid colon, the small intestine can slip into the operating area and block the surgeon's view. This trial tests a disposable isolation device that holds the small intestine away from the surgical site. Researchers compare the …
Sponsor: Beijing Friendship Hospital • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can mindfulness ease cancer stress for latino families?
Symptom relief OngoingThis study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Legal aid may ease burden for cancer caregivers
Symptom relief OngoingThis pilot study offers free legal services to caregivers and patients dealing with advanced colorectal cancer. The goal is to see if early legal support can reduce financial and emotional stress. Twenty patient-caregiver pairs will receive personalized legal help from a nonprofi…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New shot aims to quiet chemo nerve pain
Symptom relief OngoingThis study tests an injected drug called Halneuron to see if it can safely reduce nerve pain caused by chemotherapy. About 240 adults who have nerve pain from platinum or taxane chemo will receive either Halneuron or a placebo shot. The goal is to measure pain relief, sleep, fati…
Phase 2 • Sponsor: Dogwood Therapeutics Inc. • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New drug hopes to boost Radiation's punch against tough gut cancers
Symptom relief OngoingThis early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can a virtual stress program help working spouses care for cancer patients without burning out?
Symptom relief OngoingResearchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…
Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can an online program ease depression in young colorectal cancer survivors?
Symptom relief OngoingResearchers test an 8-week online precision nursing education program for young colorectal cancer survivors. The program includes Qigong exercise and mindfulness training delivered through an e-flipped classroom model. The study measures changes in depression symptoms and mindful…
Sponsor: Fooyin University • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
New program aims to restore intimacy after cancer radiation
Symptom relief PausedThis study tests a program that combines pelvic floor physical therapy with coping skills training to help women who have had pelvic radiation for cancer. The goal is to improve sexual function and quality of life. The study involves 12 cancer survivors and focuses on whether the…
Sponsor: Duke University • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Money worries in cancer care: new program aims to keep patients on track
Symptom relief OngoingThis study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Can surgery pain be managed without opioids?
Symptom relief OngoingThis trial asks whether an opioid-free anesthesia method can control acute pain after laparoscopic colorectal surgery as well as or better than standard opioid-based anesthesia. Adults aged 18 to 90 scheduled for this surgery will be randomly assigned to receive either a combinat…
Phase 1/2 • Sponsor: Hospital Universitario La Fe • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Video analysis could personalize rehab for chemo nerve damage
Symptom relief By invitation onlyThis study tests whether a personalized exercise program, guided by video-based movement analysis, can help people with chemotherapy-induced peripheral neuropathy (CIPN) — a common side effect causing numbness, tingling, and balance problems. The trial enrolls adults with breast,…
Sponsor: Seoul National University Bundang Hospital • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Intermittent fasting tested to ease radiation side effects in cancer patients
Symptom relief OngoingThis phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New app helps cancer patients fight financial toxicity
Symptom relief OngoingThis study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …
Sponsor: Lauren Hamel • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Exercise and diet may ease nerve damage and fatigue during chemo
Symptom relief OngoingThis study tests whether a tailored exercise program and nutritional guidance can reduce peripheral neuropathy (nerve damage) and fatigue in people with colorectal cancer receiving chemotherapy. Participants follow a supervised exercise routine and monthly nutrition check-ins dur…
Sponsor: St. Olavs Hospital • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Could a mushroom drink fight cancer fatigue?
Symptom relief CancelledThis pilot study investigates whether a liquid food product made from fermented mushroom extracts (AndoSanTM) can reduce fatigue in people who have had colorectal cancer. Participants with persistent moderate-to-severe fatigue will take the supplement for six weeks. Researchers w…
Sponsor: Mycotech Pharma AS • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Catheter timing could cut infections and speed recovery after colorectal surgery
Symptom relief By invitation onlyThis trial tests whether removing the urinary catheter immediately after colorectal cancer surgery (before anesthesia wears off) is as safe and effective as removing it the next day. The goal is to lower the risk of urinary tract infections and help patients recover faster. About…
Sponsor: Seoul St. Mary's Hospital • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Pre-Surgery video may calm nerves and boost understanding in colorectal cancer patients
Symptom relief By invitation onlyThis trial tests whether watching an educational video before a surgical consultation helps colorectal cancer patients feel less anxious and more informed. About 100 adults scheduled for curative-intent colon or rectal surgery will be randomly assigned to either watch the video b…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Testosterone gel trial aims to beat cancer fatigue in older men
Symptom relief OngoingThis study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…
Phase 2 • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Home monitoring may keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Soy pretzels vs. wheat pretzels: a surprising weapon against inflammation?
Symptom relief OngoingThis study compares the effects of soy soft pretzels and wheat pretzels on inflammation in 30 men with obesity. Researchers want to see if the natural chemicals in soy can reduce chronic inflammation, which is linked to health problems like cancer. Participants will eat either so…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
No more hospital trips? video nutrition counseling tested for cancer weight loss
Symptom relief OngoingThis study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…
Sponsor: King Edward Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New online training could ease bowel troubles after rectal cancer
Symptom relief OngoingThis study tests whether transanal irrigation (using water to flush the bowel) can improve quality of life and reduce bowel symptoms in 66 rectal cancer survivors who have low anterior resection syndrome (LARS). Participants learn the technique through an online platform with vir…
Sponsor: Jewish General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
One-Time biofeedback may ease bowel troubles after rectal cancer surgery
Symptom relief By invitation onlyThis study tests whether adding a single, non-invasive biofeedback session to home Kegel exercises can improve bowel control, reduce emotional distress, and enhance quality of life in people who have had rectal cancer surgery. About 66 participants will be randomly assigned to ei…
Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Phone coaching gets cancer survivors off the couch
Symptom relief OngoingThis study tests whether talking to an exercise specialist over the phone can help breast and colorectal cancer survivors become more active. Many people become less active after cancer treatment, and this program aims to change that. The trial includes 120 participants who recen…
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Could early palliative care before cancer surgery improve quality of life?
Symptom relief OngoingThis study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…
Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Home exercise boosts recovery in elderly cancer patients
Symptom relief OngoingThis study tests whether a personalized home exercise program can improve physical function and quality of life in people aged 75 and older with colorectal cancer who are having surgery. Participants receive weekly phone coaching on strength, balance, and breathing exercises from…
Sponsor: Hospital General Universitario Gregorio Marañon • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Could a plant extract make rectal cancer treatment easier to tolerate?
Symptom relief OngoingThis study tests whether adding chlorophyllin, a natural plant extract, to standard chemoradiation can reduce side effects like diarrhea, bladder irritation, and low blood counts in people with locally advanced rectal cancer. About 76 adults will receive either chlorophyllin or a…
Phase 2 • Sponsor: Tata Memorial Centre • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Can water irrigation ease Post-Cancer bowel troubles?
Symptom relief OngoingThis study compares two types of water enemas to help people with bowel leakage and urgency after rectal cancer surgery. Twenty participants will try both a high-volume system and a standard low-volume enema to see which works better. The goal is to improve quality of life and re…
Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Jun 26, 2026 17:43 UTC
-
Talking it out: team approach may ease tough cancer decisions
Symptom relief OngoingThis study tests whether an extra meeting with a team of doctors, a palliative care specialist, and a psychologist can help patients with advanced cancer feel less torn about their next treatment. 62 adults with metastatic lung, breast, colon, ovarian, or prostate cancer who need…
Sponsor: Hospital Universitario San Ignacio • Aim: Symptom relief
Last updated Jun 26, 2026 16:52 UTC
-
Blood tests could reveal secrets of rectal cancer
Knowledge-focused OngoingThis study looks at tiny pieces of cancer cells or DNA floating in the blood of people with rectal cancer. Researchers want to see if these markers can help predict how the tumor responds to standard treatment. About 341 participants, including healthy volunteers, will provide bl…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gut bacteria may hold clues to why some cancer treatments work better
Knowledge-focused PausedResearchers are building a large bank of blood and stool samples from people with advanced lung, breast, colorectal, and pancreatic cancers, plus healthy volunteers. The goal is to learn whether the mix of bacteria in a person's gut can predict how well cancer treatment works and…
Sponsor: Persephone Biosciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gut microbes may hold key to why cancer immunotherapy works for some
Knowledge-focused By invitation onlyResearchers are building a bank of blood, urine, and stool samples from 100 adults with non-small-cell lung or colorectal cancer who are receiving checkpoint inhibitor immunotherapy. Over 12 months, participants provide five samples of each type. The goal is to study how the body…
Sponsor: Persephone Biosciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Childhood farm life under the microscope: could pesticides raise cancer risk?
Knowledge-focused By invitation onlyThis study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Could a frailty score predict which older cancer patients survive intensive care?
Knowledge-focused OngoingOlder adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Late-Night snacks and booze: a recipe for colon cancer?
Knowledge-focused OngoingThis study looks at how Western habits—like drinking alcohol and eating late—might raise the risk of colorectal cancer. Twelve adults who have had colon polyps in the past will try four different weekly routines, including eating at normal times or late, with or without alcohol. …
Sponsor: Rush University Medical Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive cancer screening trial aims to cut deaths
Knowledge-focused OngoingThis study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to boost genetic testing in cancer families
Knowledge-focused OngoingThis study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study hopes to outsmart pancreatic cancer by gathering clues
Knowledge-focused OngoingThis study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Community cancer Centers' testing practices under review
Knowledge-focused CancelledThis study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New web tool aims to help cancer patients make sense of their genes
Knowledge-focused OngoingThis study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Web tool aims to empower rare cancer patients in genomic choices
Knowledge-focused OngoingThis study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused OngoingThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Early phase 1 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Robots that feel: new study tests Touch-Sensitive surgery tools
Knowledge-focused OngoingThis study watches how force feedback instruments work during robot-assisted surgeries with the da Vinci 5 system. About 200 adults having hernia, colorectal, thoracic, gynecologic, or partial kidney removal surgery will take part. The goal is to see how these tools help surgeons…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
HPV Vaccine's Long-Term effects under the microscope in costa rica
Knowledge-focused OngoingThis study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections fr…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Genetic counseling by phone may ease cancer fears in High-Risk women
Knowledge-focused PausedThis study looks at whether watching an online genetics video, with or without phone counseling from a genetic counselor, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have a…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Blood test may spot hidden cancer cells after surgery
Knowledge-focused OngoingThis pilot study is testing whether a simple blood test can detect tiny amounts of tumor DNA (ctDNA) in patients with early-stage colorectal cancer before and after surgery. The goal is to see if this test is practical and reliable for spotting any cancer cells left behind, which…
Sponsor: Anna Martling • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Gut bacteria may hold clues to anal cancer risk in hispanic HIV patients
Knowledge-focused OngoingThis completed study examined 217 Hispanic people living with HIV in California, Mexico, and Puerto Rico to see if the types of bacteria in the anus are linked to high-risk HPV infection and pre-cancerous lesions. Researchers collected anal swabs and questionnaires to compare mic…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Could a ketone drink help fight colorectal cancer? a trial investigates
Knowledge-focused OngoingThis study is testing whether a ketone supplement called beta-hydroxybutyrate (BHB) is safe and tolerable for people scheduled for a colonoscopy or flexible sigmoidoscopy as part of their standard care. Participants will take a drink containing R-1,3-butanediol three times daily …
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
15-Year safety watch for cell therapy recipients
Knowledge-focused By invitation onlyThis study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …
Phase 1 • Sponsor: USWM CT, LLC • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused OngoingThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New study explores drug cocktails for Hard-to-Treat cancers
Knowledge-focused OngoingThis study tests two different drug combinations in people with advanced colorectal, pancreatic, or leiomyosarcoma cancers that have not responded to standard treatments. Participants receive either olaparib plus durvalumab or cediranib plus durvalumab. The main goal is to unders…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New study aims to predict who can skip surgery for rectal cancer
Knowledge-focused OngoingThis pilot study is testing whether regular MRI scans and blood tests can accurately track how rectal cancer responds to pre-surgery treatment. The goal is to develop a way to predict complete remission without needing surgery. Forty adults with locally advanced rectal cancer wil…
Sponsor: Jena University Hospital • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
What does recovery really look like after aggressive peritoneal cancer surgery?
Knowledge-focused CancelledThis study follows people with colorectal cancer that has spread to the lining of the abdomen (peritoneal metastasis) or with pseudomyxoma peritonei, a rare tumor of the abdominal cavity. Participants undergo cytoreductive surgery to remove all visible tumors, followed by intrape…
Sponsor: Kyungpook National University Hospital • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Do blood thinners help or hurt when cancer meets a clot?
Knowledge-focused OngoingThis study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Veterans study aims to boost colon and liver cancer screening
Knowledge-focused By invitation onlyThis study compares two strategies to increase colon and liver cancer screening among 30,300 veterans. One approach directly reaches out to veterans to schedule tests, while the other helps healthcare providers fix system issues. Researchers will track screening rates over 12 mon…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Blood test may improve cancer care for colorectal and lung cancer patients
Knowledge-focused OngoingThis study is testing whether regular blood tests that look for tumor DNA (called liquid biopsy) can help doctors make better treatment decisions for people with advanced colorectal or lung cancer. About 332 participants will be randomly assigned to either receive standard imagin…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Blood test could decide who needs stronger or milder chemo for colorectal cancer
Knowledge-focused OngoingThis study is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors choose the right amount of chemotherapy for people with stage III colorectal cancer. About 2,450 participants will be split into groups based on their ctDNA results: those with negative c…
Phase 3 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New study tracks Cancer's genetic secrets during therapy
Knowledge-focused OngoingThis research study looks at how certain cancers (head and neck, esophagus, and anal canal) change at the genetic and immune level when patients receive chemotherapy or immunotherapy. About 39 people with advanced cancer will provide blood samples and tumor tissue over time. The …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Tumor testing could unlock personalized cancer treatments
Knowledge-focused OngoingThis study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Real-World data registry aims to map best treatment paths for advanced colorectal cancer
Knowledge-focused OngoingThis registry tracks adults with metastatic colorectal cancer who are starting their first systemic therapy. Researchers will collect information on the treatments doctors choose, how well they work, and patients' quality of life. The goal is to understand what happens in everyda…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
What do gay men know about anal cancer screening? a new survey aims to find out
Knowledge-focused OngoingThis study uses an online survey to learn what gay and bisexual men in the U.S. know about anal cancer risk and prevention. Participants answer questions about their awareness of screening options and their experiences with care. The goal is to identify gaps in knowledge and acce…
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Smartwatches for cancer survivors: a new way to track symptoms?
Knowledge-focused OngoingThis study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…
Sponsor: Laura Longshaw • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Wheat germ supplement studied for immune boost in advanced cancer
Knowledge-focused PausedThis study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…
Phase 1 • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New decision aid aims to boost colorectal cancer screening
Knowledge-focused By invitation onlyThis study is testing a decision aid tool to help patients aged 45-75 choose the right colorectal cancer screening option. Researchers will see if the tool improves shared decision-making between patients and doctors. About 400 participants from two healthcare systems in Indiana …
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Massive 30-Year Women's health study reveals hidden disease links
Knowledge-focused OngoingThis long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Colon polyp Follow-Up: 6 months vs 12 months – which is better?
Knowledge-focused By invitation onlyThis study looks at whether a 6-month or 12-month follow-up colonoscopy is better for people who had a large colon polyp (20-50 mm) removed that was not cancerous. About 546 adults will be assigned to one of the two follow-up schedules. The goal is to see which timing finds any r…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to see if patient diaries match insurance data
Knowledge-focused CancelledThis study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
MRI crystal ball for rectal cancer? study pulled before start
Knowledge-focused CancelledThis study planned to look back at MRI scans of people with rectal cancer to see if the images could predict how aggressive the cancer is and how well it responds to treatment. The goal was to create a computer model to help doctors make better decisions. However, the study was w…
Sponsor: NHS Grampian • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Rectal cancer DNA study pulled before it started
Knowledge-focused CancelledThis study aimed to see if a blood test for cancer DNA (ctDNA) could help doctors decide which patients with stage 2 or 3 rectal cancer could safely avoid surgery and just be watched closely. It also looked at using the test to catch any cancer coming back early. However, the tri…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Keytruda immune response trial aims to unlock cancer clues
Knowledge-focused OngoingThis phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Frailty check could predict chemo danger for seniors
Knowledge-focused By invitation onlyThis study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…
Sponsor: Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Mouth bacteria may predict colon cancer drug resistance
Knowledge-focused OngoingThis study examines if the amount of a bacteria called Fusobacterium nucleatum in colon cancer tumors is linked to how well patients respond to targeted therapies like cetuximab or panitumumab. Researchers will analyze stored tumor samples from 500 patients with metastatic colore…
Sponsor: Barretos Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Your DNA may push you to get that first colonoscopy
Knowledge-focused By invitation onlyThis study looks at whether telling people over 45 their genetic risk for colorectal cancer helps them decide to get their first colonoscopy. Researchers will track how many people schedule a colonoscopy after learning their risk, and compare findings like polyps between risk gro…
Sponsor: Endeavor Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Can a Team-Based tech approach boost quality of life in older cancer patients?
Knowledge-focused OngoingThis study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Gene therapy safety check: 400 cancer patients monitored for years
Knowledge-focused By invitation onlyThis study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Massive cancer survival study launched in russia
Knowledge-focused OngoingThis study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…
Sponsor: N.N. Petrov National Medical Research Center of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Laparoscopic vs open surgery: which is better for colon cancer recovery?
Knowledge-focused OngoingThis study compares open D3 surgery with laparoscopic CME surgery for right-sided colon cancer in 128 patients. The goal is to see if laparoscopic surgery leads to less pain, fewer complications, and faster recovery, while still being as effective at removing cancer. Researchers …
Sponsor: Haraldsplass Deaconess Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New study tracks pelvic changes after radiation in women with pelvic cancer
Knowledge-focused OngoingThis study follows 72 women with pelvic cancers (anal, cervical, endometrial, rectal, vaginal, or vulvar) who are receiving radiation therapy. Researchers will use pelvic exams and surveys to measure changes in vaginal health, sexual function, and quality of life over two years. …
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Local hospital reviews colorectal cancer survival data
Knowledge-focused By invitation onlyThis study looks back at the experiences of 37 people with colorectal cancer treated at a single hospital. Researchers are tracking how long patients survive after diagnosis. No new treatments are being tested; the goal is to learn from real-world outcomes.
Sponsor: University of Roma La Sapienza • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Scientists map immune landscape of liver tumors to predict cancer return
Knowledge-focused OngoingThis study looks at 64 patients with colorectal cancer that spread to the liver and was surgically removed. Researchers are analyzing tumor samples to see how different immune cells and growth patterns relate to survival and cancer recurrence. The goal is to better understand why…
Sponsor: Meng Qiu • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Emergency vs. planned stoma surgery: which leads to better quality of life?
Knowledge-focused By invitation onlyThis study looks at how well a stoma works and how it affects quality of life in people with colorectal cancer. Researchers will compare those who had a stoma created as an emergency procedure with those who had it planned ahead of time. About 700 participants will answer a quest…
Sponsor: Eva Haglind, MD, PhD, professor • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
New genetic panel could personalize cancer treatment
Knowledge-focused OngoingThis study enrolls 4,000 people with breast, ovarian, or colorectal cancer to test a comprehensive genetic panel. The panel looks for inherited cancer risks and tumor mutations that may affect drug sensitivity. Researchers aim to validate these genetic findings to potentially gui…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Simple 8-Question test may predict survival in elderly cancer patients
Knowledge-focused OngoingThis study looks at whether a quick, 8-item screening tool called G8 can help predict survival and severe side effects from treatment in elderly patients (70 years and older) with metastatic colorectal cancer. The goal is to find a simple way to identify which older patients are …
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Rural clinics test new ways to get more people screened for colon cancer
Knowledge-focused By invitation onlyThis study looks at how to improve colorectal cancer screening in rural clinics in Indiana. Clinics will mail FIT kits, send reminders, and use patient navigators to help people aged 45-75 get screened. The goal is to see which strategies work best to increase screening rates and…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Tracking childhood cancer survivors for decades to improve their future health
Knowledge-focused OngoingThis long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New blood test may predict colorectal cancer recurrence
Knowledge-focused OngoingThis study looks at whether a detailed blood test can help doctors see how well treatment is working and predict if cancer will come back in people with colorectal cancer that has spread to the liver or lungs (up to 5 spots). The test checks for tumor DNA, RNA, proteins, and othe…
Sponsor: Xiujuan Qu • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Tumor DNA study aims to unlock secrets of drug resistance
Knowledge-focused OngoingThis study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Study probes Patients' minds, not their tumors
Knowledge-focused OngoingThis study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…
Sponsor: Tomas Bata Hospital, Czech Republic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Lab test could match cancer patients to the right drugs
Knowledge-focused OngoingThis study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…
Sponsor: China Medical University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New national registry aims to improve care for rare genetic polyposis syndromes
Knowledge-focused OngoingThis study is a national registry collecting data from 1500 people with familial adenomatous polyposis (FAP) and related conditions across 28 Italian centers. It aims to better understand how these diseases progress, how they are currently managed, and what factors influence outc…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New MRI-Guided radiotherapy machine put to the test
Knowledge-focused OngoingThis study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Global study reviews brain metastasis treatments in colorectal cancer patients
Knowledge-focused OngoingThis observational study looks back at 700 patients from 15 hospitals in 2 countries to compare local treatments like surgery and radiation for brain metastases that spread from colorectal cancer. Researchers will track how long patients live and how long it takes for brain tumor…
Sponsor: Blokhin's Russian Cancer Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New online tool aims to clear up confusion around cancer screening
Knowledge-focused CancelledThis study aimed to create a web-based decision aid for people invited to cancer screening in Sweden. The tool would provide clear information about the benefits and harms of screening, helping individuals decide based on knowledge rather than fear. The study was withdrawn before…
Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
7,000 tumor samples analyzed to uncover Cancer's hidden support system
Knowledge-focused OngoingThis study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Glow-in-the-Dark dye helps surgeons find colon cancer
Knowledge-focused By invitation onlyThis trial tests a dye mixture called Luminomark, which is injected into the colon wall near a tumor during a colonoscopy. The dye glows under a special camera during surgery, helping surgeons see exactly where to cut. The study involves 30 adults with early-stage colorectal canc…
Sponsor: Seoul St. Mary's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Italy launches massive genetic database to match cancer patients with better treatments
Knowledge-focused OngoingThis observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…
Sponsor: Federation of Italian Cooperative Oncology Groups • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
96,000 adventists help uncover Diet-Cancer links
Knowledge-focused OngoingThis study follows over 96,000 Seventh-day Adventists in the U.S. and Canada to see how diet and lifestyle choices relate to breast, colorectal, and prostate cancer. Researchers are focusing on intakes of meat, soy, and dairy. Because it is observational, it can show patterns but…
Sponsor: Loma Linda University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Study aims to find safer radiation approach for rectal cancer surgery
Knowledge-focused By invitation onlyThis study looks at 266 adults with advanced rectal cancer who had radiation therapy followed by surgery. It compares standard chemoradiotherapy or short-course radiotherapy with a newer approach called total neoadjuvant treatment (TNT). The goal is to see which method leads to f…
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Blood test may spot hidden cancer DNA after surgery
Knowledge-focused OngoingThis study is testing a blood test that looks for tiny bits of cancer DNA in the blood after colorectal cancer surgery. The goal is to see if this test can predict whether the cancer will return. Over 1,000 people with stage II or III colorectal cancer will be followed for up to …
Sponsor: Exact Sciences Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Can community navigation cut cancer delays? botswana trial aims to find out
Knowledge-focused OngoingThis study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…
Phase 2 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Which surgery is best for splenic flexure cancer? new study aims to find out
Knowledge-focused By invitation onlyThis study looks at two different surgeries for a rare colon cancer located at the splenic flexure. About 140 patients will be split into two groups: one getting a smaller surgery (removing only the tumor section) and the other a larger surgery (removing more colon and lymph node…
Sponsor: Acibadem University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Can better care models keep cancer survivors healthier?
Knowledge-focused OngoingThis study looks at two new models of follow-up care for people who have finished treatment for early-stage breast or colorectal cancer. The goal is to see if these models help survivors get the recommended cancer surveillance and preventive care. About 2450 adults from Kaiser Pe…
Sponsor: Kaiser Permanente • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Experts unite to make cancer trial results easier to compare
Knowledge-focused OngoingThis study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Gut bacteria could be key to better cancer immunotherapy
Knowledge-focused OngoingThis study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Surgery or stent? new study aims to settle colon obstruction debate
Knowledge-focused By invitation onlyThis study looks at 100 adults with colon obstruction caused by cancer. It compares emergency surgery with a stent (a tube to open the blockage) to see which leads to better recovery and long-term survival. The goal is to find the best approach for this urgent condition.
Sponsor: Universidad de Zaragoza • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Blood test could replace painful biopsies for cancer patients
Knowledge-focused OngoingThis study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…
Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Walking away from cancer: study tests if exercise lowers recurrence risk
Knowledge-focused OngoingThis study looks at how moderate aerobic exercise (like brisk walking) might help prevent colorectal cancer from coming back. Researchers will measure changes in inflammation and other blood markers in 60 people who have finished cancer treatment. Participants either walk on a tr…
Sponsor: Pennington Biomedical Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New study tests tools to help families share cancer genetic results
Knowledge-focused OngoingThe IMPACT Study is testing two online tools—GeneSHARE and LivingLabReport—to help people with inherited cancer gene variants share their results with family members and follow cancer screening guidelines. The study involves 720 adults who have a genetic variant linked to cancers…
Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:58 UTC
-
Colon cancer study aims to improve treatment for older patients
Knowledge-focused OngoingThis study follows over 2,000 Korean patients with stage II or III colon cancer after surgery to see which chemotherapy treatments they actually receive and how they fare. Unlike typical clinical trials, it includes older adults and reflects real-world medical practice. The goal …
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:53 UTC
-
Robot surgery may cut complications in colorectal cancer operations
Knowledge-focused OngoingThis study looks back at data from 128,000 colorectal cancer patients in Germany to compare robot-assisted surgery with standard laparoscopic surgery. The goal is to see if robot-assisted surgery leads to fewer conversions to open surgery, fewer complications, and better long-ter…
Sponsor: Medizinische Hochschule Brandenburg Theodor Fontane • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:35 UTC
-
Simple blood test may reveal how far cancer has spread
Knowledge-focused OngoingThis study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…
Sponsor: Çanakkale Onsekiz Mart University • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:18 UTC